Retatrutide Explained: The Triple-Receptor Weight-Loss Drug in Phase 3
Retatrutide (LY3437943) is a GLP-1 + GIP + glucagon triple receptor agonist producing ~24% weight loss at 48 weeks in Phase 2 trials. Here's what it is, how it works, and where it stands.
Published Jun 14, 20264 min read
Retatrutide (LY3437943) is Eli Lilly's GLP-1 + GIP + glucagon triple receptor agonist in Phase 3 development for obesity and type 2 diabetes. Phase 2 data published in the New England Journal of Medicine showed ~24% mean body-weight reduction at 48 weeks at the 12 mg weekly dose — the largest mean weight-loss effect of any drug in modern Phase 2 trials. This explainer covers what retatrutide is, the mechanism, what the data shows, the open safety questions, and where it sits relative to Semaglutide and Tirzepatide.
For the full research profile, see Retatrutide. For the broader weight-loss landscape, see peptides for weight loss.
What it is
Retatrutide is a synthetic peptide engineered to bind and activate three receptors simultaneously:
- GLP-1 receptor — the appetite-suppression and glucose-regulation receptor that Semaglutide targets.
- GIP receptor — the second receptor Tirzepatide targets; modulates insulin response.
- Glucagon receptor — a third axis adding energy-expenditure increase to the appetite-suppression effects of GLP-1 and GIP.
The combination is the key engineering claim. GLP-1 alone (Semaglutide) reduces appetite. GLP-1 + GIP (Tirzepatide) reduces appetite slightly more and modulates insulin response. Adding glucagon (Retatrutide) layers on increased energy expenditure — the body burns more calories at rest while also eating less.
Glucagon agonism on its own would raise blood sugar (it's the hormone that releases glucose from the liver). The trick of triple agonism is that the simultaneous GLP-1 effect overrides the glucagon-driven hyperglycemia while preserving the energy-expenditure benefit.
What the data shows
Published Phase 2 data (NEJM, 2023):
| Dose (mg weekly) | Mean body-weight reduction at 48 weeks |
|---|---|
| 1 mg | ~7% |
| 4 mg | ~13% |
| 8 mg | ~17% |
| 12 mg | ~24% |
For context: Semaglutide at the comparable trial timepoint produces ~15%, Tirzepatide ~21%. Retatrutide is the largest mean effect among compounds tested at this duration.
Other notable findings:
- Significant reduction in visceral adipose tissue, not just total weight.
- Improvement in A1C in T2D cohorts (Phase 2 includes both diabetic and non-diabetic obesity arms).
- Modest improvement in lipid profile.
- Increased resting energy expenditure measured directly — consistent with the glucagon-receptor mechanism story.
Side-effect profile (Phase 2)
Broadly similar to GLP-1 monoagonists and dual agonists:
- Common: Nausea (~50% at high doses, generally improves with titration), vomiting (10–25%), diarrhea (15–25%), constipation (5–15%), reduced appetite (often desired).
- Notable: Slight heart-rate elevation (a few beats per minute on average), small increases in fasting glucose in non-diabetic patients (consistent with the glucagon component), normal-range increases in liver enzymes.
- Discontinuation rate from side effects: Higher at the 12 mg dose than lower doses, but no novel red-flag patterns emerged. Phase 3 will clarify the final tolerability picture at scale.
Where it stands
As of mid-2026, Retatrutide is in Phase 3 trials — the TRIUMPH program. Key trials:
- TRIUMPH-1 — adults with obesity (non-diabetic).
- TRIUMPH-2 — adults with obesity and T2D.
- TRIUMPH-3 — adults with obesity and cardiovascular disease.
- TRIUMPH-4 — pediatric obesity.
Lilly's stated timeline targets FDA submission in late 2026 / early 2027 with potential approval mid-2027.
The financial-market expectation is large. Tirzepatide (Mounjaro / Zepbound) is on pace to be Lilly's largest-ever drug; Retatrutide is anticipated to be larger still if the Phase 3 data holds.
How to think about it relative to current options
| Semaglutide | Tirzepatide | Retatrutide (Phase 3) | |
|---|---|---|---|
| Approval | FDA-approved | FDA-approved | Phase 3, not approved |
| Receptors | GLP-1 only | GIP + GLP-1 | GIP + GLP-1 + glucagon |
| Weight loss at maintenance | ~15% | ~21% | ~24% (Phase 2) |
| Available now? | Yes | Yes | No |
For patients currently on a weight-loss program, Retatrutide is not yet an option. The realistic timeline for clinical availability is 2027 at earliest.
What's not yet known
- Phase 3 effect size at scale. Phase 2 numbers often hold up; sometimes they don't. The Phase 3 read will be the real answer.
- Long-term safety. Particularly the glucagon-receptor component — the chronic effects of glucagon stimulation in humans at this scale are not characterized over multi-year horizons.
- Cardiovascular outcomes. Semaglutide's SELECT trial established CV benefit; Tirzepatide's SURPASS-CVOT reads 2026–2027; Retatrutide's CV trial reads later still.
- Manufacturing supply. Lilly is investing aggressively in manufacturing capacity ahead of Retatrutide approval, but the post-Wegovy / post-Mounjaro shortage history is a relevant cautionary tale.
Where to go from here
- Retatrutide research profile with study citations and per-trial detail.
- Peptides for weight loss — broader pillar with the full landscape.
- Best peptides for fat loss — ranked roundup.
- /peptides/category/weight-loss — hub with all weight-loss peptides ranked by study count.
- Are peptides safe?, peptide side effects — safety frame.
This is an informational summary of published trial data, not medical advice. Retatrutide is not currently FDA-approved or commercially available outside trials.